{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:53:08Z","timestamp":1781589188999,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01470-6","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:32:51Z","timestamp":1780554771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive multi-omics analysis identifies cancer subtypes and prognostic signatures of hepatitis B virus-associated hepatocellular carcinoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wence","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","volume":"8","author":"Polaris Observatory, C.","year":"2023","unstructured":"Polaris Observatory, C. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. Lancet Gastroenterol. Hepatol. 8, 879\u2013907 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2174\/1566523222666220825110147","volume":"24","author":"C Liu","year":"2024","unstructured":"Liu, C. et al. SHR6390 combined with cabozantinib inhibits tumor progression in the hepatocellular carcinoma mouse model. Curr. Gene Ther. 24, 453\u2013464 (2024).","journal-title":"Curr. Gene Ther."},{"key":"1470_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1731","volume":"14","author":"B Yue","year":"2024","unstructured":"Yue, B. et al. Harnessing CD8(+) T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions. Clin. Transl. Med. 14, e1731 (2024).","journal-title":"Clin. Transl. Med."},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/0113892029273682240111052317","volume":"25","author":"R Mu","year":"2024","unstructured":"Mu, R. et al. Analysis of the expression of PRDX6 in patients with hepatocellular carcinoma and its effect on the phenotype of hepatocellular carcinoma cells. Curr. Genomics 25, 2\u201311 (2024).","journal-title":"Curr. Genomics"},{"key":"1470_CR6","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","volume":"64","author":"M Levrero","year":"2016","unstructured":"Levrero, M. & Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 64, S84\u2013S101 (2016).","journal-title":"J. Hepatol."},{"key":"1470_CR7","doi-asserted-by":"publisher","unstructured":"Capasso, M., Cossiga, V., Guarino, M., Ranieri, L. & Morisco, F. The role of hepatitis viruses as drivers of hepatocancerogenesis. Cancers 16, https:\/\/doi.org\/10.3390\/cancers16081505 (2024).","DOI":"10.3390\/cancers16081505"},{"key":"1470_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000534446","volume":"13","author":"Q Du","year":"2024","unstructured":"Du, Q., Yuan, J. & Ren, Z. Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: a systematic review and meta-analysis. Liver Cancer 13, 344\u2013354 (2024).","journal-title":"Liver Cancer"},{"key":"1470_CR9","doi-asserted-by":"publisher","first-page":"e0290523","DOI":"10.1371\/journal.pone.0290523","volume":"19","author":"YH Yen","year":"2024","unstructured":"Yen, Y. H. et al. Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies. PLoS One 19, e0290523 (2024).","journal-title":"PLoS One"},{"key":"1470_CR10","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"1470_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00535-015-1126-4","volume":"51","author":"F Kawai-Kitahata","year":"2016","unstructured":"Kawai-Kitahata, F. et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J. Gastroenterol. 51, 473\u2013486 (2016).","journal-title":"J. Gastroenterol."},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/sj.onc.1210279","volume":"26","author":"SP Hussain","year":"2007","unstructured":"Hussain, S. P., Schwank, J., Staib, F., Wang, X. W. & Harris, C. C. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 26, 2166\u20132176 (2007).","journal-title":"Oncogene"},{"key":"1470_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/humu.10176","volume":"21","author":"F Staib","year":"2003","unstructured":"Staib, F., Hussain, S. P., Hofseth, L. J., Wang, X. W. & Harris, C. C. TP53 and liver carcinogenesis. Hum. Mutat. 21, 201\u2013216 (2003).","journal-title":"Hum. Mutat."},{"key":"1470_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-025-02197-9","volume":"10","author":"Q Xiao","year":"2025","unstructured":"Xiao, Q. et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct. Target Ther. 10, 151 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"1470_CR15","doi-asserted-by":"publisher","unstructured":"Milosevic, I. et al. HCV and HCC tango-deciphering the intricate dance of disease: a review article. Int. J. Mol. Sci. 24, https:\/\/doi.org\/10.3390\/ijms242216048 (2023).","DOI":"10.3390\/ijms242216048"},{"key":"1470_CR16","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/jgh.16248","volume":"38","author":"R Jacob","year":"2023","unstructured":"Jacob, R., Prince, D. S., Kench, C. & Liu, K. Alcohol and its associated liver carcinogenesis. J. Gastroenterol. Hepatol. 38, 1211\u20131217 (2023).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1470_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","volume":"74","author":"S Ha","year":"2024","unstructured":"Ha, S., Wong, V. W., Zhang, X. & Yu, J. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 74, 141\u2013152 (2024).","journal-title":"Gut"},{"key":"1470_CR18","unstructured":"Cancer Genome Atlas Research Network, Electronic address, w. b. e. & Cancer Genome Atlas Research, N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341 e1323 (2017)."},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385\u20137392 (2009).","journal-title":"Cancer Res."},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42\u201352 (2007).","journal-title":"Hepatology"},{"key":"1470_CR21","doi-asserted-by":"publisher","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","volume":"68","author":"DY Chiang","year":"2008","unstructured":"Chiang, D. Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68, 6779\u20136788 (2008).","journal-title":"Cancer Res."},{"key":"1470_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/14737159.2023.2169072","volume":"23","author":"R Chen","year":"2023","unstructured":"Chen, R., Zhou, Z., Chen, Y., Huang, A. & Chen, L. Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma. Expert Rev. Mol. Diagn. 23, 71\u201384 (2023).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1470_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/hbsn.2019.09.17","volume":"10","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients. Hepatobiliary Surg. Nutr. 10, 172\u2013179 (2021).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"1470_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.2174\/0109298665330781240830042601","volume":"31","author":"W Ye","year":"2024","unstructured":"Ye, W. et al. Association between higher expression of Vav1 in hepatocellular carcinoma and unfavourable clinicopathological features and prognosis. Protein Pept. Lett. 31, 706\u2013713 (2024).","journal-title":"Protein Pept. Lett."},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2174\/0113892029277262231108105441","volume":"24","author":"YM Xiong","year":"2023","unstructured":"Xiong, Y. M. et al. Aberrant expressions of PSMD14 in tumor tissue are the potential prognostic biomarkers for hepatocellular carcinoma after curative resection. Curr. Genomics 24, 368\u2013384 (2023).","journal-title":"Curr. Genomics"},{"key":"1470_CR26","doi-asserted-by":"publisher","first-page":"560229","DOI":"10.3389\/fonc.2020.560229","volume":"10","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q., Yu, X., Zheng, Q., He, Y. & Guo, W. A molecular subtype model for liver HBV-related hepatocellular carcinoma patients based on immune-related genes. Front. Oncol. 10, 560229 (2020).","journal-title":"Front. Oncol."},{"key":"1470_CR27","doi-asserted-by":"publisher","unstructured":"Dantzer, C. et al. Emerging role of oncogenic ss-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma. Elife 13, https:\/\/doi.org\/10.7554\/eLife.95191 (2024).","DOI":"10.7554\/eLife.95191"},{"key":"1470_CR28","doi-asserted-by":"publisher","first-page":"4248","DOI":"10.1038\/onc.2014.358","volume":"34","author":"M Shriver","year":"2015","unstructured":"Shriver, M. et al. Loss of giant obscurins from breast epithelium promotes epithelial-to-mesenchymal transition, tumorigenicity and metastasis. Oncogene 34, 4248\u20134259 (2015).","journal-title":"Oncogene"},{"key":"1470_CR29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201506039","volume":"8","author":"Y Guan","year":"2016","unstructured":"Guan, Y. et al. CRISPR\/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse. EMBO Mol. Med. 8, 477\u2013488 (2016).","journal-title":"EMBO Mol. Med."},{"key":"1470_CR30","doi-asserted-by":"publisher","unstructured":"Ishikawa, T., Kitano, H., Mamiya, A., Kokubun, S. & Hidai, C. The first EGF domain of coagulation factor IX attenuates cell adhesion and induces apoptosis. Biosci. Rep. 36, https:\/\/doi.org\/10.1042\/BSR20160098 (2016).","DOI":"10.1042\/BSR20160098"},{"key":"1470_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04569-3","volume":"13","author":"P Carpintero-Fernandez","year":"2022","unstructured":"Carpintero-Fernandez, P. et al. Genome wide CRISPR\/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence. Cell Death Dis. 13, 163 (2022).","journal-title":"Cell Death Dis."},{"key":"1470_CR32","doi-asserted-by":"publisher","first-page":"R953","DOI":"10.1186\/bcr1325","volume":"7","author":"Y Pawitan","year":"2005","unstructured":"Pawitan, Y. et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7, R953\u2013964 (2005).","journal-title":"Breast Cancer Res."},{"key":"1470_CR33","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.1073\/pnas.0902232106","volume":"106","author":"M Sheffer","year":"2009","unstructured":"Sheffer, M. et al. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc. Natl. Acad. Sci. USA. 106, 7131\u20137136 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1470_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/JHC.S156701","volume":"5","author":"AM Khalaf","year":"2018","unstructured":"Khalaf, A. M. et al. Role of Wnt\/beta-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J. Hepatocell. Carcinoma 5, 61\u201373 (2018).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"1470_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1160\/TH11-12-0875","volume":"108","author":"M Caspers","year":"2012","unstructured":"Caspers, M. et al. Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. Thromb. Haemost. 108, 247\u2013257 (2012).","journal-title":"Thromb. Haemost."},{"key":"1470_CR36","first-page":"3658","volume":"19","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Knockdown of serpin peptidase inhibitor clade C member 1 inhibits the growth of nasopharyngeal carcinoma cells. Mol. Med. Rep. 19, 3658\u20133666 (2019).","journal-title":"Mol. Med. Rep."},{"key":"1470_CR37","first-page":"e2079","volume":"7","author":"Z Le","year":"2024","unstructured":"Le, Z., Chen, S., Feng, Y., Lu, W. & Liu, M. SERPINC1, a new prognostic predictor of colon cancer, promote colon cancer progression through EMT. Cancer Rep. 7, e2079 (2024).","journal-title":"Cancer Rep."},{"key":"1470_CR38","doi-asserted-by":"publisher","first-page":"933646","DOI":"10.3389\/fonc.2022.933646","volume":"12","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Synergistic effects of nab-PTX and anti-PD-1 antibody combination against lung cancer by regulating the Pi3K\/AKT pathway through the Serpinc1 gene. Front. Oncol. 12, 933646 (2022).","journal-title":"Front. Oncol."},{"key":"1470_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s11658-025-00724-8","volume":"30","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Troxerutin suppresses the stemness of osteosarcoma via the CD155\/SRC\/beta-catenin signaling axis. Cell Mol. Biol. Lett. 30, 45 (2025).","journal-title":"Cell Mol. Biol. Lett."},{"key":"1470_CR40","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/s41401-025-01524-8","volume":"46","author":"YF Liu","year":"2025","unstructured":"Liu, Y. F. et al. CYP2A6 suppresses hepatocellular carcinoma via inhibiting SRC\/Wnt\/beta-Catenin pathway. Acta Pharm. Sin. 46, 2029\u20132040 (2025).","journal-title":"Acta Pharm. Sin."},{"key":"1470_CR41","doi-asserted-by":"publisher","unstructured":"Fu, Y. et al. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance. Elife 13, https:\/\/doi.org\/10.7554\/eLife.95009 (2024).","DOI":"10.7554\/eLife.95009"},{"key":"1470_CR42","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1002\/hep.32740","volume":"77","author":"R Donne","year":"2023","unstructured":"Donne, R. & Lujambio, A. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma. Hepatology 77, 1773\u20131796 (2023).","journal-title":"Hepatology"},{"key":"1470_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0976-4","volume":"18","author":"C Wei","year":"2019","unstructured":"Wei, C. et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol. Cancer 18, 64 (2019).","journal-title":"Mol. Cancer"},{"key":"1470_CR44","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1158\/0008-5472.CAN-19-1972","volume":"79","author":"M Saini","year":"2019","unstructured":"Saini, M., Szczerba, B. M. & Aceto, N. Circulating tumor cell-neutrophil tango along the metastatic process. Cancer Res. 79, 6067\u20136073 (2019).","journal-title":"Cancer Res."},{"key":"1470_CR45","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba, B. M. et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566, 553\u2013557 (2019).","journal-title":"Nature"},{"key":"1470_CR46","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng.3547","volume":"48","author":"A Fujimoto","year":"2016","unstructured":"Fujimoto, A. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500\u2013509 (2016).","journal-title":"Nat. Genet."},{"key":"1470_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cell.2019.08.052","volume":"179","author":"Q Gao","year":"2019","unstructured":"Gao, Q. et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179, 561\u2013577 e522 (2019).","journal-title":"Cell"},{"key":"1470_CR48","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127 (2007).","journal-title":"Biostatistics"},{"key":"1470_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccell.2019.07.001","volume":"36","author":"Z Qiu","year":"2019","unstructured":"Qiu, Z. et al. A pharmacogenomic landscape in human liver cancers. Cancer Cell 36, 179\u2013193 e111 (2019).","journal-title":"Cancer Cell"},{"key":"1470_CR50","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1093\/bioinformatics\/btaa1018","volume":"36","author":"X Lu","year":"2021","unstructured":"Lu, X., Meng, J., Zhou, Y., Jiang, L. & Yan, F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics 36, 5539\u20135541 (2021).","journal-title":"Bioinformatics"},{"key":"1470_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28421-6","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat. Commun. 13, 816 (2022).","journal-title":"Nat. Commun."},{"key":"1470_CR52","doi-asserted-by":"publisher","first-page":"e29084","DOI":"10.1002\/jmv.29084","volume":"95","author":"X Peng","year":"2023","unstructured":"Peng, X., Shi, Y., Zhang, B., Xu, C. & Lang, J. Establishment of nucleic acid sensing pathways-based model in predicting response to immunotherapy and targeted drug in hepatitis virus-related hepatocellular carcinoma. J. Med. Virol. 95, e29084 (2023).","journal-title":"J. Med. Virol."},{"key":"1470_CR53","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.25011\/cim.v44i3.37124","volume":"44","author":"J Shen","year":"2021","unstructured":"Shen, J. et al. A six-gene prognostic risk prediction model in hepatitis B virus-associated hepatocellular carcinoma. Clin. Invest. Med. 44, E32\u2013E44 (2021).","journal-title":"Clin. Invest. Med."},{"key":"1470_CR54","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12876-023-03026-5","volume":"23","author":"P Yan","year":"2023","unstructured":"Yan, P. et al. Establishment of a prognostic signature based on fatty acid metabolism genes in HCC associated with hepatitis B. BMC Gastroenterol. 23, 390 (2023).","journal-title":"BMC Gastroenterol."},{"key":"1470_CR55","doi-asserted-by":"publisher","first-page":"1142319","DOI":"10.3389\/fimmu.2023.1142319","volume":"14","author":"J Dong","year":"2023","unstructured":"Dong, J. et al. The necroptosis related gene LGALS3 can be used as a biomarker for the adverse progression from chronic HBV infection to HCC. Front. Immunol. 14, 1142319 (2023).","journal-title":"Front. Immunol."},{"key":"1470_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-022-00470-y","volume":"17","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Construction and validation of prognostic signature for hepatocellular carcinoma basing on hepatitis B virus related specific genes. Infect. Agent Cancer 17, 60 (2022).","journal-title":"Infect. Agent Cancer"},{"key":"1470_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s10020-020-00185-z","volume":"26","author":"Q Fang","year":"2020","unstructured":"Fang, Q. & Chen, H. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma. Mol. Med. 26, 60 (2020).","journal-title":"Mol. Med."},{"key":"1470_CR58","first-page":"2391265","volume":"2022","author":"Z Gao","year":"2022","unstructured":"Gao, Z. et al. A novel metabolism-related gene signature for predicting the prognosis of HBV-infected hepatocellular carcinoma. J. Oncol. 2022, 2391265 (2022).","journal-title":"J. Oncol."},{"key":"1470_CR59","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.7150\/jca.31287","volume":"10","author":"X Liao","year":"2019","unstructured":"Liao, X. et al. Comprehensive investigation of key biomarkers and pathways in hepatitis B virus-related hepatocellular carcinoma. J. Cancer 10, 5689\u20135704 (2019).","journal-title":"J. Cancer"},{"key":"1470_CR60","doi-asserted-by":"publisher","first-page":"1411161","DOI":"10.3389\/fimmu.2024.1411161","volume":"15","author":"J Tian","year":"2024","unstructured":"Tian, J. et al. Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes. Front. Immunol. 15, 1411161 (2024).","journal-title":"Front. Immunol."},{"key":"1470_CR61","doi-asserted-by":"publisher","first-page":"654517","DOI":"10.3389\/fgene.2021.654517","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Identification of key genes associated with the process of hepatitis B inflammation and cancer transformation by integrated bioinformatics analysis. Front. Genet. 12, 654517 (2021).","journal-title":"Front. Genet."},{"key":"1470_CR62","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng, D. et al. IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures. Front. Immunol. 12, 687975 (2021).","journal-title":"Front. Immunol."},{"key":"1470_CR63","doi-asserted-by":"publisher","unstructured":"Yang, C. et al. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform. 22, https:\/\/doi.org\/10.1093\/bib\/bbaa164 (2021).","DOI":"10.1093\/bib\/bbaa164"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01470-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01470-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01470-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:09:59Z","timestamp":1781586599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01470-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01470-6","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}